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Abstract
Background: More than one-half of coronary artery disease (CAD) patients have low HDL cholesterol despite having
well-managed LDL cholesterol. Almond supplementation has not been shown to elevate circulating HDL cholesterol
concentrations in clinical trials, perhaps because the baseline HDL cholesterol of trial subjects was not low.
Objective: This clinical trial was designed to test the effect of almond supplementation on low HDL cholesterol in CAD
patients.
Methods: A total of 150 CAD patients (50 per group), with serum LDL cholesterol #100 mg/dL and HDL cholesterol
#40 mg/dL in men and#50 mg/dL in women, were recruited from the Aga Khan University Hospital. After recording vital
signs and completing a dietary and physical activity questionnaire, patients were randomly assigned to 1 of the following
3 groups: the no-intervention group (NI), the Pakistani almonds group (PA), and the American almonds group (AA). The
respective almond varieties (10 g/d) were given to patients with instructions to soak them overnight, remove the skin, and
eat them before breakfast. Blood samples for lipid profiling, body weight, and blood pressure were collected, and
assessment of dietary patterns was done at baseline, week 6, and week 12.
Results: Almonds significantly increased HDL cholesterol. At weeks 6 and 12, HDL cholesterol was 12–14% and 14–16%
higher, respectively, in the PA and AA than their respective baselines. In line with previous reports, serum concentrations
of total cholesterol, triglycerides, LDL cholesterol, and VLDL cholesterol; total-to-HDL and LDL-to-HDL cholesterol ratios,
and the atherogenic index were reduced in both the PA and AA at weeks 6 and 12 compared with baseline (P < 0.05).
Effects on serum lipids did not differ between the 2 almond groups. Dietary patterns, body weight, and blood pressure did
not change in any of the 3 groups during the trial.
Conclusion: A low dose of almonds (10 g/d) consumed before breakfast can increase HDL cholesterol, in addition to
improving other markers of abnormal lipid metabolism in CAD patients with low initial HDL cholesterol. This trial was
registered at the Australian New Zealand Clinical Trial Registry as ACTRN12614000036617. J Nutr 2015;145:2287–92.
Keywords: almond varieties, low-dose, empty stomach, soaked, parallel design, optimal LDL cholesterol
Introduction
Low circulating HDL cholesterol concentrations are prevalent
throughout the world, particularly in the Asian population (1), and
the insufficiency of therapeutic options signifies the need to explore
new avenues to counter the pathologic consequences of low HDL
cholesterol(2).Approximately35–39%ofthepopulationoftheUnited
States (3) and 33–40% of the population in the United Kingdom (4)
haveserumHDLcholesterolbelownormal. InPakistan, theprevalence
of lowHDL cholesterol is reported to be as high as 60–80% (5).
Recommendations for management of low HDL cholesterol
include both pharmacologic and nonpharmacologic approaches.
Tolerability and safety issues of pharmacotherapies limit their use
(6). Hepatotoxicity (7) and hyperglycemia (8) caused by niacin, gall-
stone formation (9) and myopathies (10) by fibrates, and hyperten-
sion (11)andelevationofaldosteroneandcortisol (12)by torcetrapib
(inhibitors of cholesteryl ester transfer protein), among others, are
some of the problems calling for alternativemeasures to address low
HDL cholesterol.
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Nonpharmacologic strategies are shown to raise HDL choles-
terol by 10–15% (13). Such strategies include regular exercise
(14), weight reduction (15), cessation of smoking (16), and
dietary modifications characterized by intake of fewer saturated
fats (17), more unsaturated fats (18), high fiber, and vitamins.
Almonds fit this profile because they are rich inmonounsaturated
fats, fiber, and vitamin E (19).
Along with other nuts, almonds are approved by the FDA
because they have the potential to significantly reduce cardiovas-
cular disease risk (20). A meta-analysis of lipid-neutralizing
potential concluded that dietary almonds decrease serum choles-
terol,witha strong trend to lowerLDLcholesterol [P-trend=0.05),
but do not affectHDL cholesterol (21). The almond trials included
in this meta-analysis, as well as others reporting serum lipid
concentrations, were conducted in participants who were normo-
lipidemic (22–27), prediabetic and/or diabetic (26, 28, 29), obese
(30), and/or hyperlipidemic (31–34), without having low HDL
cholesterol at baseline. It seems desirable to investigate the HDL
cholesterol–raising potential of almonds in a population that has
low HDL cholesterol at baseline (35), such as South Asians.
This clinical trial was conducted in coronary artery disease
(CAD)8 patients. Even with well-maintained LDL cholesterol in
CAD patients, low HDL cholesterol remains an independent
indicator of cardiovascular disease risk (36). Almost one-half of
CAD patients at the time of hospitalization have normal LDL
cholesterol but low HDL cholesterol (37). The aim of this
randomized controlled clinical trial was to test the effect of
almonds on HDL cholesterol in CAD patients starting with low
HDL cholesterol.
Methods
Participants. Eligibilitycriteria includedCADpatientswithoptimalLDL
cholesterol (#100mg/dL) and lowHDLcholesterol (men#40mg/dLand
women#50 mg/dL) (37). Patients were prediagnosed by their respective
cardiologists to haveCADbased on the following criteria: history of acute
myocardial infarction, percutaneous coronary intervention, or coronary
arterybypassgrafting;evidenceof silentmyocardial infarctiononthebasis
of Q waves on an electrocardiogram or elevated troponins >0.1 mg/L;
evidence of myocardial ischemia or infarction as shown either by
segmental wall motion abnormalities on a stress echo or reversible or
fixed perfusion defects on a myocardial perfusion imaging study; or CAD
onangiography.Exclusioncriteria includedpatientspresentingwithacute
myocardial infarction in theprevious5wk, regular nut consumers (>15g/d;
3 d/wk), and/or patients with a nut allergy. The recruited participants were
men (n = 113) and women (n = 37) aged 32–86 y with a mean bodyweight
of 76 6 12 kg and serum HDL cholesterol of 33 6 6 mg/dL in men and
36 6 6 mg/dL in women.
Study design. Ethical approval for this clinical trial (2230-Med-ERC-
12) was obtained from the Ethical Review Committee, Aga Khan
University, Karachi (ACTRN12614000036617).
A sample size (n=36per group)was calculatedwith theuseof previous
reportsof a6%HDLcholesterol improvement fromalmondconsumption
(30). The power of the study to detect significant improvement in HDL
cholesterolwas80%,witha significance levelof5%.FiftyCADpatients in
each of 3 groups (total n = 150) were recruited from Cardiology Clinics,
Aga Khan University Hospital, Karachi, Pakistan from February to June
2012.
Themedical records of patientswere checked for eligibility, and recent
lipid profiles (within the previous 4 wk) were considered. After obtaining
informed consent, patients were randomly assigned (computer-generated
block randomization) to 1 of the following 3 groups: the no-intervention
group (NI) (control), the Pakistani almonds group (PA), or the American
almonds group (AA). Participants in the NI were not given almonds and
were instructed not to consume other nuts during their enrollment in the
trial. Pakistani and American almonds were dispensed to participants in
thePAandAA, respectively, for 6wk. Patient diarieswere alsoprovided to
record daily almond consumption. Compliance was monitored through
regular phone calls (2 times/wk).
All participantswere requested to followthe recommendationsof their
respective cardiologists, including drug regimens. At baseline, vital signs
and prescribed drug regimens were noted. FFQs and lifestyle patterns
(physical activity) were also collected. A nonfasting blood sample (5 ml)
was drawn for lipid profiling.
The first follow-up visits were at week 6 (63 d), at which nonfasting
blood sampleswere drawn; blood pressure andbodyweight, among other
variables, were measured; any change in medications was noted; lifestyle
(i.e., physical activity patterns) and FFQs were filled out, and patients
diaries were collected. Almonds, along with patients diaries for the next
6 wk, were dispatched to participants in the PA and AA.
At the final follow-up at week 12 (63 d), blood samples, vital signs,
changes in drug regimens, food consumption, exercise patterns, and
patients diaries were collected. Almonds were provided to the NI only
after the completion of the trial (final follow-up at week 12).
Almond intervention. The Pakistani almond variety used in this study
was Talwar (sword-shaped), which is grown around the region ofQuetta,
the capital city of Balochistan province. Locally available imported
American almonds (Carmel variety, California Shelled) were obtained
from the Utility Store of Defense Housing Society in Karachi. Almonds
were dispensed in the form of preweighed packets (10 g/d). Participants
were instructed to soak the almonds overnight and eat them after
removing the skin, before breakfast (presumably on an empty stomach).
Selection of this dose and mode was based on the traditional recommen-
dation, in which 7 almonds are eaten early in the morning.
Biochemical analysis. Serum was separated from the blood samples of
nonfasting subjects collected at baseline and the 2 follow-up visits by
centrifuging at 2000 3 g for 15 min at 4C. Aliquots of these serum
samples were stored at 280 C until further analysis. Concentrations of
total cholesterol, TGs, andLDLandHDLcholesterolweremeasuredwith
the use of a c-111 automated analyzer (Roche Cobas) and commercially
available kits (38). VLDL cholesterol concentrations (VLDL cholesterol =
TGs/5), the atherogenic index (AI) (AI = non-HDL cholesterol/HDL
cholesterol), and total-to-HDL cholesterol and LDL-to-HDL cholesterol
ratios were calculated (38).
Statistical analysis. Data were analyzed with the use of SPSS version
17.0 and GraphPad Prism; results are presented as means6 SEMs. Two-
factor repeated-measures ANOVAwas used to comparemeans of groups,
followed by Bonferroni post hoc tests. For categorical data, a chi-square
test was used to compare differences between groups. Trends in HDL
cholesterol response to dietary treatments were tested with the use of
multivariate linear regression, keepingHDLcholesterol as the fixed factor
andnutrients (macro-andmicro-) asdependentvariables.APvalue<0.05
was considered statistically significant (95% CI).
Results
Follow-up was 75.3%. Reasons for attrition are presented in
Figure 1, which also shows the flow of patients through the trial.
As expected, no adverse effects were reported to be associated
with almond consumption. The age, weight, and nutrient profile
of patients at baseline is provided in Supplemental Table 1.
Drug regimensdid not differ between groups andalso remained
fairly constantover time. Similarly, nomajor change in the typeand
intensity of physical activity, as per the questionnaire records, was
noted over time for the participants of the 3 groups. Dietary
patterns remained fairly constant throughout the trial durationand
among the 3 groups.
8 Abbreviations used: AA, American almonds group; AI, atherogenic index; CAD,
coronary artery disease; NI, no-intervention group; PA, Pakistani almonds group.
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The almond interventions significantly increased serum HDL
cholesterol concentrations. At week 6, there were 16% and 14%
increases in the HDL cholesterol concentration in the PA and AA
compared with their respective baseline values (Figure 2A). At
week 12,HDL cholesterol increased 22%and 21% in the PA and
AA compared with their respective baseline concentrations
(Figure 2B).
The PA and AA had 11% and 9% higher HDL cholesterol
concentrations, respectively, than theNI at week 6, and 15%and
13% higher concentrations, respectively, at week 12 (Table 1).
The effect on HDL cholesterol did not differ between the 2
almond groups.
The almond interventions caused a significant decrease (P <
0.05) in serum lipid concentrations (TGs and total, LDL, and
VLDL cholesterol), at both week 6 and week 12 (Figure 2)
when compared with NI. Similarly, the almond interventions
significantly decreased total-to-HDL and LDL-to-HDL cho-
lesterol ratios and the AI at weeks 6 and 12, compared with
their respective baseline values (Figure 2), with no difference
between the PA and AA. Systolic and diastolic blood pressure
and body weight remained fairly constant in the 3 groups over
time.
Discussion
Toour knowledge, this is the first randomized controlled clinical
trial with almonds that showed marked improvement in
low serum HDL cholesterol in CAD patients. A meta-analysis
showed that almond administration had no effect on HDL
cholesterol (21), perhaps because most of the previous trials
included healthy (24), hyperlipidemic (31), obese (39), or
diabetic (26) individuals whose baseline HDL cholesterol was
not particularly low.
Although the serum cholesterol and LDL cholesterol of trial
participants werewithin normal ranges (mostly fromuse of lipid-
lowering therapy), the almond interventions further reduced
lipidemia, which is not uncommon (27). TGs, VLDL cholesterol,
total-to-HDL and LDL-to-HDL cholesterol ratios, and the AI
were lowered by consuming only 10 g/d of either almond variety.
This is in line with previous reports, in which a high dose of
almond supplementation had a similar response (33).
Almond consumption has been shown to lower serum lipids in
a dose-dependent manner, with every 10 g/d corresponding to a
1% LDL cholesterol reduction (21). We observed a relatively
higher reduction in serum lipids, which could be explained by the
following: 1) the CAD patients were already on lipid-lowering
therapies, whichmay have synergistic effects on serum lipids; and
2) the mode of almond consumption varied. Previously, almonds
were mostly added to foods such as, e.g., cereals and muffins (24,
31),whereaswe recommended thatalmondsbe eatenonanempty
stomach (early in the morning, before breakfast). A number of
recent studies have also recommended the preferential use of
almonds as snacks (40), on an empty stomach (41, 42).
Whereas patients were given 10 g/d almonds in the current
study, the lowest amount previously used was 25 g/d, which was
powderedandadded tomeals (33).Groundalmondsare shown to
have higher bioaccessibility of active contents (43), but the food
matrix is known to hinder the gastrointestinal absorption of these
contents (44). Participantsof this trial usedwholealmonds,which
maybe hard to digest (45), but prolonged residence in the gutmay
have a prebiotic effect (46, 47). Mastication of whole almonds
enhances bioavailability (48), promoting satiety (49) and limiting
FIGURE 1 The flow of participants enrolled in
the clinical trial analyzing the HDL cholesterol–
raising effect of almond supplementation, par-
ticipant random assignment and allocation (to
either the no-intervention, American almonds, or
Pakistani almonds group), and their follow-up
visits.
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food intake, thereby preventingweight gain (50). Thismay be the
underpinning reasonwhyweobserved that the bodyweight of the
participants did not change over time.
Patterns of dietary consumptionwere not changedover time in
the study, although habitual almond consumption is reported to
induce favorable dietary modifications, such as an increase in the
FIGURE 2 Percentage changes in serum
lipids, lipoproteins, and ratios from baseline, at
week 6 (A) and week 12 (B) in coronary artery
disease patients in the NI, PA, or AA. Values are
means 6 SEMs; n = 34 in the NI, n = 38 in the
PA, and n = 41 in the AA. a . b . c, where
means without a common letter differ, P ,
0.05. AA, American almonds group; AI, athero-
genic index; HDL-C, HDL cholesterol; LDL-C,
LDL cholesterol; NI, no-intervention group; PA,
Pakistani almond group; TC, total cholesterol;
VLDL-C, VLDL cholesterol.
TABLE 1 Body weight, blood pressure, and serum lipids of coronary artery disease patients enrolled in the NI, PA, or AA at baseline,
week 6, and week 121
NI PA AA
Baseline Week 6 Week 12 Baseline Week 6 Week 12 Baseline Week 6 Week 12
Body weight, kg 73.4 6 0.2a,x 73 6 0.3a,x 73 6 0.5a,x 79 6 0.2a,x 79 6 0.2a,y 78 6 0.2a,y 75 6 0.2a,x 74 6 0.1a,y 74 6 0.2a,y
Blood pressure, mm Hg
Systolic 127 6 0.4a,x 128 6 0.5a,x 126 6 1a,x 126 6 2a,x 126 6 2a,y 124 6 3a,y 128 6 3a,x 127 6 2a,y 125 6 3a,y
Diastolic 70 6 0.2a,x 71 6 0.3a,x 70 6 2a,x 67 6 1a,x 67 6 0.5a,y 66 6 1a,y 68 6 1a,x 67 6 0.2a,y 67 6 1a,y
HDL-C, mg/dL 33.9 6 6c,x 34.6 6 6b,x 35.3 6 6b,x 33 6 5c,x 38.5 6 6a,y 40.5 6 7a,y 33 6 5c,x 37.6 6 6a,y 40.0 6 6a,y
LDL-C, mg/dL 57 6 10a,x 53.5 6 9b,x 52.0 6 9b,x 57 6 9a,x 36.6 6 6c,y 33.4 6 5c,y 626 6 9a,x 37.2 6 6c,y 36.4 6 6c,y
TC, mg/dL 121 6 21a,x 117 6 20b,x 116 6 20b,x 119 6 19a,x 101 6 16c,y 98 6 16c,y 121 6 19a,x 102 6 16c,y 100 6 16c,y
TG, mg/dL 149 6 26a,x 144 6 25b,x 145 6 25b,x 142 6 23a,x 130 6 21c,y 120 6 19c,y 130 6 20a,x 122 6 19c,y 118 6 18c,y
VLDL-C, mg/dL 30 6 5a,x 29 6 5b,x 29 6 5b,x 28 6 5a,x 26 6 4c,y 24 6 4c,y 26 6 4a,x 24 6 4c,y 23 6 4c,y
TC:HDL-C ratio 3.6 6 0.6a,x 3.4 6 0.6b,x 3.3 6 0.6b,x 3.7 6 0.6a,x 2.7 6 0.4c,y 2.5 6 0.4c,y 3.7 6 0.6a,x 2.7 6 0.4c,y 2.6 6 0.4c,y
LDL-C:HDL-C ratio 1.7 6 0.3a,x 1.56 6 0.3b,x 1.47 6 0.2b,x 1.8 6 0.3a,x 0.97 6 0.1c,y 0.87 6 0.1c,y 1.9 6 0.3a,x 1.05 6 0.1c,y 0.95 6 0.1c,y
Atherogenic index2 1.9 6 0.3a,x 1.87 6 0.3b,x 1.86 6 0.3b,x 1.9 6 0.3a,x 1.70 6 0.3c,y 1.61 6 0.3c,y 1.8 6 0.3a,x 1.66 6 0.3c,y 1.62 6 0.3c,y
1 Values are means6 SEMs; NI, n = 50 baseline and n = 34 at weeks 6 and 12; PA, n = 50 at baseline and n = 38 at weeks 6 and 12; AA, n = 50 at baseline and n = 41 at weeks 6
and 12; a . b . c, where labeled means for a group without a common letter differ, P , 0.05; x . y, where labeled means in a group at a time without a common letter differ P ,
0.05. AA, American almonds group; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; NI, no-intervention group; PA, Pakistani almonds group; TC, total cholesterol; VLDL-C, VLDL
cholesterol.
2 Calculated as the ratio of non–HDL-C and HDL-C.
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consumption unsaturated fats, fibers, and vitamins, with a
decrease in the consumption of saturated fats, sodium, and sugar
(27). A probable explanation for this ambiguity could be that,
unlike the free-living, presumably healthy subjects from the latter
study, CAD patients from the current trial had already modified
their dietary patterns according to general recommendations for
lipid neutralization. The 12 wk duration and low dose (10 g/d)
may also be insufficient for changing dietary intake.
InSouthAsian tradition, almonds are considered tobe ageneral
health tonic;;7almonds (10 g) are soakedovernight, peeled in the
morning, and eaten before breakfast (51). The participants of this
study were instructed to follow the same approach based on the
general acceptance of thismodeof consumption inour population.
Comparison of almond varieties in this trial was based on
efficacy,whereas, in previous studies, varieties were compared on
the basis of composition or in vitro antioxidant potential (52, 53).
Despite the fact that previous reports showed minor composi-
tional differences between varieties, our results indicate that the
medicinal effects are fairly similar.
In conclusion, almond supplementation can markedly im-
prove low HDL cholesterol, in addition to reducing other serum
lipids. To our knowledge, this is the first study of almond varieties
in CAD patients showing efficacy in a lower dose (10 g/d) of
almonds givenonan empty stomach.This studypresents almonds
as a cost-effective complementary treatment strategy for low
HDL cholesterol, which requires lifelong management.
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